Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ajovy as add-on to Botox in chronic migraine
NCT05724771Phase 4Active, not recruiting
- Sponsor
- Chicago Headache Center and Research Institute
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fremanezumab in chronic migraine, sponsored by Chicago Headache Center and Research Institute. Primary endpoint: Monthly Migraine Days at 6 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
fremanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT05724771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724771.